Recruiting
A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring - IM047-003
Updated:
7 May, 2025
|
ClinicalTrials.gov
Gender(s)
Age Range
Location(s)
Recruiting
Inclusion Criteria: - Diagnosis of Multiple sclerosis (MS) - Currently or recently pregnant - Reside in the United States, Canada or Germany. Exclusion Criteria: • Exposure to other S1P therapies, cladribine, or mitoxantrone during the first trimester. Other protocol-defined inclusion/exclusion criteria apply
If you want to report a side effect, you can report directly to the Danish Medicines Agency via the website www.meldenbivirkning.dk
We recommend that you also contact BMS to report side effects.
Side effects and other reportable events are defined here
Report side effects or product quality complaints: Medical Information
466-DK-2200001